<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20050518102049+02'00'</creation_date><modification_date>D:20060322172725+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-285_h_a_dec_1.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 13-v-2005 c(2005)1521 
 not for publication</p></section><section><header>commission decision of 13-v-2005 
 amending the marketing authorisation for &quot;apidra - insulin glulisine&quot;, a medicinal 
 product for human use, granted by decision c(2004)3653</header><p>only the german text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 13-v-2005 
 amending the marketing authorisation for &quot;apidra - insulin glulisine&quot;, a medicinal 
 product for human use, granted by decision c(2004)3653 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorisation and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the first subparagraph of article 6(10) thereof, 
 having regard to the application submitted by aventis pharma deutschland gmbh on 17 
 december 2004 under article 6(1) of commission regulation (ec) no 1085/2003, 
 having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 3, and in particular article 61(3) thereof, 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 16 march 2005, 
 whereas: 
 (1)</p><p>an examination of the major variation type ii to the terms of the marketing 
 authorisation for the medicinal product &quot;apidra - insulin glulisine&quot;, which is 
 entered in the community register of medicinal products under no(s) 
 eu/1/04/285/001-020 and the placing on the market of which was authorised by</p><p>
 1 oj l 214, 24.8.1993, p. 1. regulation as last amended by [regulation (ec) no 1647/2003 (oj l 245, 29.9.2003, p. 19)]. 
 2 oj l 159, 27.6.2003, p. 24. 3 oj l 311, 28.11.2001, p. 67. directive as last amended by [directive 2004/27/ec (oj l 136, 30.4.2004, p. 34).]</p></section><section><header>en  
   en</header><p>decision c(2004)3653 of 27 september 2004, has shown that the product remains in compliance with the requirements set out in directive 2001/83/ec of the 
 european parliament and of the council of 6 november 2001 on the community 
 code relating to medicinal products for human use
 4. (2)</p><p>it is therefore appropriate to accept the application in respect of a major variation 
 to the terms of the marketing authorisation and to amend decision c(2004)3653 
 accordingly. 
 (3)</p><p>during the same period, aventis pharma deutschland gmbh submitted, under 
 article 61(3) of directive 2001/83/ec, a notification(s) for changes to an aspect 
 of the labelling or the package leaflet. the competent authority did not oppose the 
 proposed change within the 90-day time-limit. 
 (4)</p><p>the marketing authorisation should be updated, and decision c(2004)3653 
 amended accordingly. 
 (5)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c (2004)3653 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)3653 is amended as follows: 1) the list of notifications for changes to an aspect of the labelling or the package leaflet, 
 accepted between 15 march 2005 and 16 march 2005, is added to the updated marketing 
 authorisation; 
 application number 
 annex (eu numbers affected) 
 emea/h/c/000557/n/0003 iiia (eu/1/04/285/001-020) 
 2) annex i is replaced by the text set out in the annex i to this decision. 
 3) annex iii is replaced by the text set out in the annex iii to this decision. 
 4) the following numbers are added to article 1 and entered in the community register 
 of medicinal products: 
 eu/1/04/285/021 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-1 cartridge</p><p>
 4 oj l 311, 28.11.2001, p. 67. directive as last amended by [directive 2004/27/ec (oj l 136, 30.4.2004, p.34)].</p></section><section><header>en  
   en</header><p>eu/1/04/285/022 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-3 cartridges 
 eu/1/04/285/023 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-4 cartridges 
 eu/1/04/285/024 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-5 cartridges 
 eu/1/04/285/025 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-6 cartridges 
 eu/1/04/285/026 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-8 cartridges 
 eu/1/04/285/027 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-9 cartridges 
 eu/1/04/285/028 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass) for opticlik-3 ml-10 cartridges 
 article 2 this decision is addressed to aventis pharma deutschland gmbh, brueningstrasse 50, d-65926 frankfurt am main, deutschland. 
 done at brussels, 13-v-2005 
 for the commission g√ºnter verheugen 
 member of the commission</p></section></body></xml>